This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Insulin aspart
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='PDB ID [[4gbc]]' scene='96/968809/Cv/3'> | <StructureSection load='' size='340' side='right' caption='PDB ID [[4gbc]]' scene='96/968809/Cv/3'> | ||
| - | Insulin aspart, sold under the brand name NovoLog and Fiasp, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. See also [https://en.wikipedia.org/wiki/Insulin_aspart]. | + | Insulin aspart, sold under the brand name NovoLog and Fiasp, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. See also [https://en.wikipedia.org/wiki/Insulin_aspart]. |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:12, 6 June 2023
| |||||||||||
